Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).
Full description
Treatment:
Once patients are diagnosed with grade II~IV acute GVHD, the combination therapy should be initiated as soon as possible.
Methylprednisolone: 2mg/kg/d, iv or iv gtt, in two or three divided doses. Taper steroid every one or two weeks according to patient's response. Ruxolitinib 5~10mg bid po for at least 28 days. If patient's ANC<0.5×10e9/L or PLT< 20×10e9/L, cease ruxolitinib until recovery of ANC higher than 0.5×10e9/L or PLT higher than 20×10e9/L.
Indication for stopping Ruxolitinib treatment:
No response after ruxolitinib treatment for 28 days. Develop life-threatening complication. ANC<0.5×10e9/L or PLT< 20×10e9/L.
Indication for second line acute GVHD treatment:
deterioration of acute GVHD in 3 days no response after 7 days no complete remission after 2 weeks.
Suggestions of second line therapy:
Basiliximab 20mg, d1, d4, d8.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Jieling Jiang, M.D.; Liping Wan, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal